Dyslipidemia Market Epidemiology 2023 Forecasts Report

DALLAS, October 21, 2014 /PRNewswire/ --

RnRMarketResearch.com adds EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023 market research of 94 pages to the Therapeutics section under Pharmaceuticals category of its online business intelligence library. To build the epidemiological forecast for the total prevalent cases of dyslipidemia in the 8MM, epidemiologists used nationally representative studies that provided the total prevalence of serum lipid disturbances (LDLc, TG, and HDLc) using the National Cholesterol Education Program (NCEP) guidelines for the detection, evaluation, and treatment of high blood cholesterol in adults (part of the Adult Treatment Panel III [ATP III]). To build the epidemiological forecast for the total prevalent cases of FH in the 8MM, epidemiologists selected the best available studies from peer reviewed journals that provided the total prevalence of FH using the Simon Broome Classification criteria, or the LDLc based criteria. The forecast methodology is consistent across the 8MM, thereby allowing for a meaningful forecast comparison of the total prevalent cases of dyslipidemia as well as the total prevalent cases of FH in these markets. Complete report is available at http://www.rnrmarketresearch.com/epicast-report-dyslipidemia-epidemiology-forecast-to-2023-market-report.html .

The EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023 research report forecasts that the total prevalent cases of dyslipidemia in the 8MM will increase from 572,418,492 total prevalent cases in 2013, to 685,905,635 total prevalent cases in 2023, at an Annual Growth Rate (AGR) of 1.99%. All markets will see an increase in the total prevalent cases of dyslipidemia at varying AGRs, except for Germany, which will see a decrease. The 8MM had an estimated 3,339,447 total prevalent cases of FH in 2013, and the number of total prevalent cases is expected to increase to 4,365,831 by 2023, at an AGR of 3.07%. All markets will see an increase in the total prevalent cases of FH at varying AGRs, except for Japan, which will see a decrease.

The total prevalent cases of increased LDLc (=115mg/dL to =160mg/dL based on country-specific cut-offs) in the 8MM for 2013 and 2023. The research forecasts that the total prevalent cases of increased LDLc in the 8MM will increase from 345,008,543 total prevalent cases in 2013 to 411,737,455 total prevalent cases in 2023, at an AGR of 1.93%. All markets will see an increase in the total prevalent cases of increased LDLc at varying AGRs, except for Germany, which will see a decrease. The total prevalent cases of very high TG (=500mg/dL) in the 8MM for 2013 and 2023. The 8MM had an estimated 10,777,756 total prevalent cases of very high TG in 2013, and the number of total prevalent cases is expected to increase to 12,746,492 by 2023, at an AGR of 1.83%. All markets will see an increase in the total prevalent cases of very high TG at varying AGRs, except for Germany and Japan, which will see a decrease.

The Dyslipidemia EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for dyslipidemia in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China [urban]). It includes a 10-year epidemiological forecast for the total prevalent cases of dyslipidemia (defined as: increased low-density lipoprotein cholesterol [LDLc], high triglycerides [TG] [=200mg/dL], or low levels of high-density lipoprotein cholesterol [HDLc]), as well as the total prevalent cases of increased LDLc (=115mg/dL to =160mg/dL based on country-specific cut-offs), and very high TG (=500mg/dL), segmented by sex and age (in 10-year intervals beginning at 20 years and ending at =70 years). Additionally, the forecast provides the total prevalent cases of familial hypercholesterolemia (FH) in these markets. The dyslipidemia epidemiology report is written and developed by Mastersand PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM. Order a copy of this research at http://www.rnrmarketresearch.com/contacts/purchase?rname=232644 .

Reasons to buy this report: Develop business strategies by understanding the trends shaping and driving the global dyslipidemia market. Quantify patient populations in the global dyslipidemia market to improve product design, pricing, and launch plans. Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for dyslipidemia therapeutics in each of the markets covered.

List of Tables 

Table 1: Risk Factors and Comorbidities for Dyslipidemia 15
Table 2: Overview of the Total Prevalence of Low HDLc in the 5EU 18
Table 3: NCEP-ATP III Classification of LDLc, TG, and HDLc 20
Table 4: Simon Broome Diagnostic Criteria for FH 21
Table 5: LDLc Based Definition of FH 21
Table 6: Sources of Total Prevalence Data for FH in the 8MM 22
Table 7: Sources of Total Prevalence Data for Increased LDLc in the 8MM 23
Table 8: Sources of Total Prevalence Data for High TG (?200mg/dL) in the 8MM 24
Table 9: Sources of Total Prevalence Data for Very High TG (?500mg/dL) in the 8MM 25
Table 10: Sources of Total Prevalence Data for Low HDLc in the 8MM 26
Table 11: 8MM, Sources Not Used in the Epidemiological Analysis of Dyslipidemia 34
Table 12: 8MM, Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ?20 Years, N, 2013-2023 61
Table 13: 8MM, Age-Specific Total Prevalent Cases of Dyslipidemia, Both Sexes, N (Row %), 2013 62
Table 14: 8MM, Sex-Specific Total Prevalent Cases of Dyslipidemia, Ages ?20 Years, N (Row %), 2013 64
Table 15: 8MM, Total Prevalent Cases of Familial Hypercholesterolemia, Both Sexes, Ages ?20 Years, N, 2013-2023 66
Table 16: 8MM, Total Prevalent Cases of Increased LDLc* (?115mg/dL to ?160mg/dL), Both Sexes, Ages ?20 Years, N, 2013-2023 68
Table 17: 8MM, Age-Specific Total Prevalent Cases of Increased LDLc* (?115mg/dL to ?160mg/dL), Both Sexes, N (Row %), 2013 70
Table 18: 8MM, Sex-Specific Total Prevalent Cases of Increased LDLc* (?115mg/dL to ?160mg/dL), Ages ?20 Years, N (Row %), 2013 72
Table 19: 8MM, Total Prevalent Cases of Very High TG (?500mg/dL), Both Sexes, Ages ?20 Years, N, 2013-2023 75
Table 20: 8MM, Age-Specific Total Prevalent Cases of Very High TG (?500mg/dL), Both Sexes, N (Row %), 2013 76
Table 21: 8MM, Sex-Specific Total Prevalent Cases of Very High TG (?500mg/dL), Ages ?20 Years, N (Row %), 2013 78

List of Figures 

Figure 1: 8MM, Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ?20 Years, N, 2013-2023 61
Figure 2: 8MM, Age-Specific Total Prevalent Cases of Dyslipidemia, Both Sexes, Ages ?20 Years, N, 2013 63
Figure 3: 8MM, Sex-Specific Total Prevalent Cases of Dyslipidemia, Ages ?20 Years, N, 2013 64
Figure 4: 8MM, Age-Standardized Total Prevalence of Dyslipidemia (%), Ages ?20 Years, by Sex, 2013 65
Figure 5: 8MM, Total Prevalent Cases of Familial Hypercholesterolemia, Both Sexes, Ages ?20 Years, N, 2013-2023 67
Figure 6: 8MM, Total Prevalent Cases of Increased LDLc* (?115mg/dL to ?160mg/dL), Both Sexes, Ages ?20 Years, N, 2013-2023 68
Figure 7: 8MM, Age-Specific Total Prevalent Cases of Increased LDLc* (?115mg/dL to ?160mg/dL), Both Sexes, Ages ?20 Years, N, 2013 71
Figure 8: 8MM, Sex-Specific Total Prevalent Cases of Increased LDLc* (?115mg/dL to ?160mg/dL), Ages ?20 Years, N, 2013 73
Figure 9: 8MM, Age-Standardized Total Prevalence of Increased LDLc (?115mg/dL to ?160mg/dL)* (%), Ages ?20 Years, by Sex, 2013 74
Figure 10: 8MM, Total Prevalent Cases of Very High TG (?500mg/dL), Both Sexes, Ages ?20 Years, N, 2013-2023 75
Figure 11: 8MM, Age-Specific Total Prevalent Cases of Very High TG (?500mg/dL), Both Sexes, Ages ?20 Years, N, 2013 77
Figure 12: 8MM, Sex-Specific Total Prevalent Cases of Very High TG (?500mg/dL), Ages ?20 Years, N, 2013 78
Figure 13: 8MM, Age-Standardized Total Prevalence of Very High TG (?500mg/dL) (%), Ages ?20 Years, by Sex, 2013 79

Explore more reports on the pharmaceuticals industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

About Us: 

RnRMarketResearch.com provides syndicated market research reports (500,000+) and in-depth studies of over 5000 micro markets. Not limited to any one industry, we offer research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:  

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441
sales@rnrmarketresearch.com